Segment and Geographic Area Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Dec. 31, 2021	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Disaggregation of Revenue
Net revenues			$ 56,197		$ 45,804		$ 33,266
Total net revenues		$ 14,886	56,197		45,804		33,266
United States
Disaggregation of Revenue
Net revenues			43,510		34,879		23,907
All other
Disaggregation of Revenue
Net revenues			2,673		2,923		2,068
Immunology | Humira
Disaggregation of Revenue
Net revenues			20,694		19,832		19,169
Immunology | Humira | United States
Disaggregation of Revenue
Net revenues			17,330		16,112		14,864
Immunology | Humira | International
Disaggregation of Revenue
Net revenues			3,364		3,720		4,305
Immunology | Skyrizi
Disaggregation of Revenue
Net revenues			2,939		1,590		355
Immunology | Skyrizi | United States
Disaggregation of Revenue
Net revenues			2,486		1,385		311
Immunology | Skyrizi | International
Disaggregation of Revenue
Net revenues			453		205		44
Immunology | Rinvoq
Disaggregation of Revenue
Net revenues			1,651		731		47
Immunology | Rinvoq | United States
Disaggregation of Revenue
Net revenues			1,271		653		47
Immunology | Rinvoq | International
Disaggregation of Revenue
Net revenues			380		78		0
Hematologic Oncology | Imbruvica
Disaggregation of Revenue
Net revenues			5,408		5,314		4,674
Hematologic Oncology | Imbruvica | United States
Disaggregation of Revenue
Net revenues			4,321		4,305		3,830
Hematologic Oncology | Imbruvica | International
Disaggregation of Revenue
Collaboration revenues			1,087		1,009		844
Hematologic Oncology | Venclexta
Disaggregation of Revenue
Net revenues			1,820		1,337		792
Hematologic Oncology | Venclexta | United States
Disaggregation of Revenue
Net revenues			934		804		521
Hematologic Oncology | Venclexta | International
Disaggregation of Revenue
Net revenues			886		533		271
Aesthetics | Botox Cosmetic
Disaggregation of Revenue
Net revenues	[1]		2,232		1,112		0
Aesthetics | Botox Cosmetic | United States
Disaggregation of Revenue
Net revenues	[1]		1,424		687		0
Aesthetics | Botox Cosmetic | International
Disaggregation of Revenue
Net revenues	[1]		808		425		0
Aesthetics | Juvederm Collection
Disaggregation of Revenue
Net revenues	[1]		1,535		718		0
Aesthetics | Juvederm Collection | United States
Disaggregation of Revenue
Net revenues	[1]		658		318		0
Aesthetics | Juvederm Collection | International
Disaggregation of Revenue
Net revenues	[1]		877		400		0
Aesthetics | Other Aesthetics
Disaggregation of Revenue
Net revenues	[1]		1,466		760		0
Aesthetics | Other Aesthetics | United States
Disaggregation of Revenue
Net revenues	[1]		1,268		666		0
Aesthetics | Other Aesthetics | International
Disaggregation of Revenue
Net revenues			198	[1]	94	[1]	0
Neuroscience | Botox Therapeutic
Disaggregation of Revenue
Net revenues	[1]		2,451		1,387		0
Neuroscience | Botox Therapeutic | United States
Disaggregation of Revenue
Net revenues	[1]		2,012		1,155		0
Neuroscience | Botox Therapeutic | International
Disaggregation of Revenue
Net revenues	[1]		439		232		0
Neuroscience | Vraylar | United States
Disaggregation of Revenue
Net revenues	[1]		1,728		951		0
Neuroscience | Duodopa
Disaggregation of Revenue
Net revenues			511		494		461
Neuroscience | Duodopa | United States
Disaggregation of Revenue
Net revenues			102		103		97
Neuroscience | Duodopa | International
Disaggregation of Revenue
Net revenues			409		391		364
Neuroscience | Ubrelvy | United States
Disaggregation of Revenue
Net revenues	[1]		552		125		0
Neuroscience | Other Neuroscience
Disaggregation of Revenue
Net revenues	[1]		685		539		0
Neuroscience | Other Neuroscience | United States
Disaggregation of Revenue
Net revenues	[1]		667		528		0
Neuroscience | Other Neuroscience | International
Disaggregation of Revenue
Net revenues	[1]		18		11		0
Eye Care | Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	[1]		579		378		0
Eye Care | Lumigan/Ganfort | United States
Disaggregation of Revenue
Net revenues	[1]		273		165		0
Eye Care | Lumigan/Ganfort | International
Disaggregation of Revenue
Net revenues	[1]		306		213		0
Eye Care | Alphagan/Combigan
Disaggregation of Revenue
Net revenues	[1]		529		326		0
Eye Care | Alphagan/Combigan | United States
Disaggregation of Revenue
Net revenues	[1]		373		223		0
Eye Care | Alphagan/Combigan | International
Disaggregation of Revenue
Net revenues	[1]		156		103		0
Eye Care | Restasis
Disaggregation of Revenue
Net revenues	[1]		1,290		787		0
Eye Care | Restasis | United States
Disaggregation of Revenue
Net revenues	[1]		1,234		755		0
Eye Care | Restasis | International
Disaggregation of Revenue
Net revenues	[1]		56		32		0
Eye Care | Other Eye Care
Disaggregation of Revenue
Net revenues	[1]		1,169		693		0
Eye Care | Other Eye Care | United States
Disaggregation of Revenue
Net revenues	[1]		523		305		0
Eye Care | Other Eye Care | International
Disaggregation of Revenue
Net revenues	[1]		646		388		0
Women's Health | Lo Loestrin
Disaggregation of Revenue
Net revenues	[1]		437		356		0
Women's Health | Lo Loestrin | United States
Disaggregation of Revenue
Net revenues	[1]		423		346		0
Women's Health | Lo Loestrin | International
Disaggregation of Revenue
Net revenues	[1]		14		10		0
Women's Health | Orilissa/Oriahnn
Disaggregation of Revenue
Net revenues			145		125		93
Women's Health | Orilissa/Oriahnn | United States
Disaggregation of Revenue
Net revenues			139		121		91
Women's Health | Orilissa/Oriahnn | International
Disaggregation of Revenue
Net revenues			6		4		2
Women's Health | Other Women's Health
Disaggregation of Revenue
Net revenues	[1]		214		192		0
Women's Health | Other Women's Health | United States
Disaggregation of Revenue
Net revenues	[1]		209		181		0
Women's Health | Other Women's Health | International
Disaggregation of Revenue
Net revenues	[1]		5		11		0
Other Key Products | Mavyret
Disaggregation of Revenue
Net revenues			1,710		1,830		2,893
Other Key Products | Mavyret | United States
Disaggregation of Revenue
Net revenues			754		785		1,473
Other Key Products | Mavyret | International
Disaggregation of Revenue
Net revenues			956		1,045		1,420
Other Key Products | Creon | United States
Disaggregation of Revenue
Net revenues			1,191		1,114		1,041
Other Key Products | Lupron
Disaggregation of Revenue
Net revenues			783		752		887
Other Key Products | Lupron | United States
Disaggregation of Revenue
Net revenues			604		600		720
Other Key Products | Lupron | International
Disaggregation of Revenue
Net revenues			179		152		167
Other Key Products | Linzess/Constella
Disaggregation of Revenue
Net revenues	[1]		1,038		667		0
Other Key Products | Linzess/Constella | United States
Disaggregation of Revenue
Net revenues	[1]		1,006		649		0
Other Key Products | Linzess/Constella | International
Disaggregation of Revenue
Net revenues	[1]		32		18		0
Other Key Products | Synthroid | United States
Disaggregation of Revenue
Net revenues			$ 767		$ 771		$ 786

[1] Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.